LifeMine Gets Funding, Inks Discovery Alliance With GSK
Deal Snapshot: The fungi-derived medicine firm signed a three-candidate discovery and development deal with GlaxoSmithKline, which also contributed to its $175m series C round.
You may also be interested in...
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.